Enumeral Biomedical uses a nanotechnology-enabled process for therapeutic discovery, immune profiling and personalized medicine. Founded by Nisa Leung in 2009, Enumeral Biomedical is backed by investors that include 180 Degree Capital and Montrose Capital Partners and is headquartered in New York.